(Press-News.org) AUDIO:
For years, researchers have known that two key proteins tend to characterize Alzheimer's disease in the brain. Amyloid makes up the senile plaques that form in the brains of Alzheimer's...
Click here for more information.
An international team of Alzheimer's disease experts, led by Washington University School of Medicine in St. Louis, has uncovered a gene variation that appears to predict the rate at which Alzheimer's disease will progress.
The investigators report their findings online in the journal Public Library of Science (PLoS) Genetics.
Whereas previous studies have focused on factors that influence the risk for Alzheimer's, the new research points to a way to determine how rapidly Alzheimer's patients may develop full-blown dementia after their diagnosis.
The investigators studied 846 patients with elevated levels of a protein called tau in their cerebrospinal fluid (CSF). Recent studies have found that the presence of a particular form of the tau protein in the CSF is an indicator of Alzheimer's disease. The researchers also looked at single DNA variations in the patients and identified a genetic marker linked to elevated tau levels. That marker turned out to be associated with rapid progression of Alzheimer's disease.
"People who carry this genetic marker tend to have higher tau levels at any given stage of the disease than individuals without it," says senior investigator Alison M. Goate, DPhil., the Samuel and Mae S. Ludwig Professor of Genetics in Psychiatry. "Until now, most studies of genetic risks associated with Alzheimer's disease have looked at the risk of developing the disease, not the speed at which you will progress once you have it. The genetic marker we've identified deals with progression."
For many patients and their families, that information may be more useful than the knowledge that a person may be developing Alzheimer's damage in the brain even if that individual hasn't yet developed clinical symptoms, according to Goate. Damage from the disease can be present for years before symptoms appear. But this study suggests that elevated tau, combined with the genetic marker, could be a sign that clinical symptoms may quickly advance from mild impairment to severe dementia.
The study advances recent research that found it was possible to diagnose Alzheimer's disease, even in patients with no clinical symptoms, by measuring levels of the amyloid beta protein in the CSF. A-beta makes up the senile plaques that form in the brains of Alzheimer's patients, but it turns out that low levels of A-beta in the CSF predict the presence of Alzheimer's pathology in the brain.
Meanwhile, the tau protein collects in the other abnormal brain structures that characterize the illness, called neurofibrillary tangles. The tangles cause brain cells to die, and when those cells die, tau is released into the CSF. So just as low A-beta levels in the CSF are associated with Alzheimer's disease, elevated tau levels also indicate the presence of disease.
"Tau also can be released in stroke patients or those with other types of brain injuries," says first author Carlos Cruchaga, PhD. "However, a particular form of tau is specific to Alzheimer's. It's a phosphorylated form of the protein called ptau. Other neurodegenerative conditions, like Parkinson's disease, don't produce elevated ptau in the CSF. It's only found in Alzheimer's disease."
Cruchaga, an assistant professor of psychiatry at Washington University, says there was no association between ptau and overall Alzheimer's disease risk or age of onset for Alzheimer's patients, but there was a significant association between a variant of a gene that plays a role in modifying the tau protein, ptau levels in the CSF and the rate at which the disease progressed.
"We have looked at data from three separate, international studies, and in all three, we found the same association," Cruchaga says. "So we are confident that it is real and that this gene variant is associated with progression in Alzheimer's disease."
He says the genetic finding, combined with the ability to measure ptau in the CSF may mean that if drugs could inhibit the protein's accumulation in the fluid, it might prevent or delay some of the devastation associated with Alzheimer's disease.
"If we could somehow decrease tau pathology in those individuals who also have low levels of A-beta in the CSF, we might be able to slow the progression of the disease," Cruchaga says.
Goate says the findings might initially be most useful in the design of clinical trials. If researchers knew in advance that particular study patients were going to progress at a rapid rate, they could better evaluate the effects of drugs designed to slow the progression of Alzheimer's disease.
"I think that if the drug target is A-beta, then treatment really needs to begin even before someone develops symptoms," Goate says. "In contrast, since most of the changes in tau occur after someone already has symptoms, it may be possible to target that pathway to slow progression of the disease, by interfering with the actions of the tau protein."
INFORMATION:
Cruchaga C, et al. SNPs association with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genetics, vol. 6 (9). Sept. 16, 2010. www.plosgenetics.org
This work was supported by grants from AstraZeneca, National Institute on Aging, Barnes-Jewish Hospital Foundation, Ford Foundation, Department of Veterans Affairs. Carlos Cruchaga has a fellowship from "Fundacion Alfonso Martin Escudero."
This work is also pending a patent filed by Washington University in St. Louis, in which C. Cruchaga, AM Goate, DM Holtzman and A. Fagan are named as inventors. The patent is currently under option to AstraZeneca Pharmaceuticals LP. Goate and Holtzman were consultants for AstraZeneca Pharmaceuticals LP in 2008/2009.
Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.
Researchers identify genetic marker of aggressive Alzheimer's disease
2010-09-17
ELSE PRESS RELEASES FROM THIS DATE:
Development aid for maternal, newborn and child health doubled over 5 years
2010-09-17
Health experts will today call for a greater prioritization and targeting of aid to save the lives of mothers, newborns, and children in poor countries.
The amount of official development assistance (ODA) to maternal, newborn and child health (MNCH) in developing countries doubled between 2003 and 2008, but its ratio to overall aid for health remained static. The US, UK, EU, GAVI and the Global Fund have made the largest absolute increases, while Spain and a number of small bilateral donors including New Zealand and Belgium have made significant percentage increases, ...
Rising education levels among women save children's lives worldwide
2010-09-17
SEATTLE –Women are advancing further in school than at any time in recent history, a trend that is having a tremendous impact on child mortality, according to new research from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.
Between 1970 and 2009, mortality in children under age 5 dropped from 16 million to 7.8 million annually, and IHME researchers estimate that 51% of the reduction can be linked to increased education among women of reproductive age. This means that 4.2 million fewer children died in 2009 because women received ...
Popular supplements to combat joint pain do not work
2010-09-17
Two popular supplements taken by millions of people around the world to combat joint pain, do not work, finds research published on bmj.com today.
The supplements, glucosamine and chondroitin, are either taken on their own or in combination to reduce the pain caused by osteoarthritis in hips and knees.
The researchers, led by Professor Peter Jüni at the University of Bern in Switzerland, argue that given these supplements are not dangerous "we see no harm in having patients continue these preparations as long as they perceive a benefit and cover the cost of treatment ...
Attitudes must change if we are to achieve a good death for all, say experts
2010-09-17
Society's attitudes towards dying, death and bereavement need to change if we are to achieve a good death for all, say experts in a special series of articles published on bmj.com today in the first BMJ "Spotlight" supplement.
By 2030 the annual number of deaths around the world is expected to rise from 58 million to 74 million, but too many people still die alone, in pain, without dignity, or feeling alienated.
The articles aim to remedy this by exploring how lessons learnt from end of life care for cancer patients can be adapted for those dying from chronic conditions ...
Researchers raise concerns over the increasing commercialization of science
2010-09-17
The increasing commercialisation of science is restricting access to vital scientific knowledge and delaying the progress of science, claim researchers on bmj.com today.
Varuni de Silva and Raveen Hanwella from the University of Colombo in Sri Lanka argue that copyrighting or patenting medical scales, tests, techniques and genetic material, limits the level of public benefit from scientific discovery.
For example, they found that many commonly used rating scales are under copyright and researchers have to pay for their use.
Some genetic tests also carry patents, ...
Case Western Reserve researcher discovers new 'anti-pathogenic' drugs to treat MRSA
2010-09-17
CLEVELAND – September 16, 2010 – Menachem Shoham, PhD, associate professor and researcher in the department of biochemistry at the Case Western Reserve University School of Medicine, has identified new anti-pathogenic drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) harmless by preventing the production of toxins that cause disease.
Infections of MRSA are a growing public health problem causing 20,000 deaths per year in the U.S. alone. MRSA is the most prevalent bacterial pathogen in hospital settings and in the community ...
UCI scientists decode genomes of sexually precocious fruit flies
2010-09-17
Irvine, Calif., Sept. 16, 2010 — UC Irvine researchers have deciphered how lowly fruit flies bred to rapidly develop and reproduce actually evolve over time. The findings, reported in the Sept. 15 online issue of Nature, contradict the long-held belief that sexual beings evolve the same way simpler organisms do and could fundamentally alter the direction of genetic research for new pharmaceuticals and other products.
"This is actually decoding the key DNA in the evolution of aging, development and fertility," said ecology & evolutionary biology professor Michael Rose, ...
Tornado-chasing becomes vacation choice, MU researchers find
2010-09-17
COLUMBIA, Mo. -- Instead of heading to the coast for vacation, people are traveling to Tornado Alley. The number of people registering to get a closer look at tornadoes is growing as vacationers trade in their beach towels for a ride with storm chasers. Labeled "Tornado Tourists" by a University of Missouri research team, these travelers are searching for an experience beyond just thrills.
Sonja Wilhelm Stanis and Carla Barbieri, associate professors in the School of Natural Resources Department of Parks, Recreation and Tourism in the MU College of Agriculture, Food ...
'Nanosprings' offer improved performance in biomedicine, electronics
2010-09-17
CORVALLIS, Ore. – Researchers at Oregon State University have reported the successful loading of biological molecules onto "nanosprings" – a type of nanostructure that has gained significant interest in recent years for its ability to maximize surface area in microreactors.
The findings, announced in the journal Biotechnology Progress, may open the door to important new nanotech applications in production of pharmaceuticals, biological sensors, biomedicine or other areas.
"Nanosprings are a fairly new concept in nanotechnology because they create a lot of surface area ...
Avoiding dangerous climate change: An international perspective
2010-09-17
The world will need to make substantial reductions in greenhouse gas emissions below current levels over the next few decades if the worst impacts of dangerous climate change are to be avoided. This was a key conclusion from UK and US climate scientists at an international workshop on the UK AVOID program in Washington, DC exploring the most policy-relevant aspects of understanding dangerous climate change.
Latest results from AVOID have shown that strong mitigation action to limit temperature rise to below 2 °C avoids many of the climate impacts, but not all of them. ...